ASX:PYC PYC Therapeutics (PYC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About PYC Therapeutics Stock (ASX:PYC) 30 days 90 days 365 days Advanced Chart Get PYC Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationA$611.26 millionP/E RatioN/ADividend Yield9.46%Price TargetN/AConsensus RatingN/A Company Overview PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia. Read More Receive PYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PYC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PYC Stock News HeadlinesPYC Therapeutics Advances Clinical Trials for PKD TreatmentAugust 7 at 7:49 PM | tipranks.comPYC Therapeutics Updates Investors in Q3 WebinarJuly 31, 2025 | tipranks.comAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump policy move, and the other tied to a proven financial pattern that previously minted over 80,000 new millionaires. He believes a small $900 investment could turn into a $108,000 windfall within 12 months—and this may be the last chance for everyday investors to catch it. | Paradigm Press (Ad)PYC Therapeutics to Host Investor Webinar on Q3 ProgressJuly 27, 2025 | tipranks.comPYC Therapeutics Advances Clinical Trials for PKD TreatmentJuly 6, 2025 | tipranks.comPYC Therapeutics Advances Phelan-McDermid Syndrome ProgramJune 26, 2025 | tipranks.comPYC Therapeutics Advances VP-001 with FDA Trial Design ApprovalJune 22, 2025 | tipranks.comPYC Therapeutics Advances Clinical Trial for PKD TreatmentMay 25, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PYC CIKN/A Webpyctx.com Phone61 8 6151 0992FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$37.73 million Net Margins-171.02% Pretax MarginN/A Return on Equity-68.34% Return on Assets-37.83% Debt Debt-to-Equity Ratio1.38 Current Ratio9.40 Quick Ratio8.93 Sales & Book Value Annual SalesA$22.06 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares4,670,000,000Free FloatN/AMarket CapA$611.26 million OptionableNot Optionable Beta0.71 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (ASX:PYC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PYC Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share PYC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
